Drugs that contain Buprenorphine Hydrochloride; Naloxone Hydrochloride

1. Drug name - BUNAVAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine Aug, 2032

(9 years from now)

US9522188 BDSI Abuse resistant transmucosal drug delivery device Apr, 2035

(12 years from now)

Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence

Dosage: FILM;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 2.1MG BASE;EQ 0.3MG BASE FILM;BUCCAL Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE FILM;BUCCAL Discontinued
EQ 6.3MG BASE;EQ 1MG BASE FILM;BUCCAL Discontinued

2. Drug name - SUBOXONE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10285910 INDIVIOR INC Sublingual and buccal film compositions Oct, 2022

(5 days from now)

US8017150 INDIVIOR INC Polyethylene oxide-based films and drug delivery systems made therefrom Feb, 2023

(4 months from now)

US8603514 INDIVIOR INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions Apr, 2024

(1 year, 5 months from now)

US9687454 INDIVIOR INC Sublingual and buccal film compositions Aug, 2029

(6 years from now)

US11135216 INDIVIOR INC Sublingual and buccal film compositions Aug, 2029

(6 years from now)

US8475832 INDIVIOR INC Sublingual and buccal film compositions Mar, 2030

(7 years from now)

Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 2MG BASE;EQ 0.5MG BASE FILM;BUCCAL, SUBLINGUAL Prescription
EQ 4MG BASE;EQ 1MG BASE FILM;BUCCAL, SUBLINGUAL Prescription
EQ 8MG BASE;EQ 2MG BASE FILM;BUCCAL, SUBLINGUAL Prescription
EQ 12MG BASE;EQ 3MG BASE FILM;BUCCAL, SUBLINGUAL Prescription

3. Drug name - ZUBSOLV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8658198 OREXO US INC Non-abusable pharmaceutical composition comprising opioids Dec, 2027

(5 years from now)

US8470361 OREXO US INC Non-abusable pharmaceutical composition comprising opioids May, 2030

(7 years from now)

US11020387 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US11020388 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US8940330 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US9439900 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US9259421 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US10874661 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

US10946010 OREXO US INC Abuse-resistant pharmaceutical composition for the treatment of opioid dependence Sep, 2032

(9 years from now)

Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone; Use of zubsolv for treatment of opioid dependence

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 0.7MG BASE;EQ 0.18MG BASE TABLET;SUBLINGUAL Prescription
EQ 1.4MG BASE;EQ 0.36MG BASE TABLET;SUBLINGUAL Prescription
EQ 2.9MG BASE;EQ 0.71MG BASE TABLET;SUBLINGUAL Prescription
EQ 5.7MG BASE;EQ 1.4MG BASE TABLET;SUBLINGUAL Prescription
EQ 8.6MG BASE;EQ 2.1MG BASE TABLET;SUBLINGUAL Prescription
EQ 11.4MG BASE;EQ 2.9MG BASE TABLET;SUBLINGUAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.